Form 4 for TXG 10x Genomics, Inc.
Accepted 2026-08-13 16:11:23 ET · period of report 2026-08-11 · accession 0001610717-26-000358 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-08-13 16:11 | 2026-08-11 | TXG | STUELPNAGEL JOHN R | Dir | S - Sale | $57.75 | -20.0K | 348.4K | -5% | -$1.16M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-08-11 | S | D | 17,000 | $57.58 | 351,436 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $57.50 to $58.1525. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Class A Common Stock | 2026-08-11 | S | D | 3,000 | $58.73 | 348,436 | D | — | — |